CBAY - CymaBay Therapeutics' Lead Drug Candidate Hits Main Goal In Pivotal Study For Liver Damage | Benzinga
CymaBay Therapeutics Inc (NASDAQ: CBAY) released topline results from its Phase 3 pivotal RESPONSE study of seladelpar for adult patients with primary biliary cholangitis (PBC).
PBC is a chronic disease in which the small bile ducts in the liver become inflamed and are eventually destroyed. When no bile ducts exist, bile builds up and causes liver damage.
Also Read: Genfit's Miss Is CymaBay Therapeutics' Gain: Analyst Says Rival Data Leaves ...